Gene markers for lung cancer

Abstract

A method for the diagnosis and identification of new or residual lung cancer is disclosed which uses newly identified markers for lung cancer including syndecan 1, collagen 1 alpha 2, and two novel proteins, 7013 and 7018. The method involves identification of the lung cancer markers is blood from a patient. It is envisioned that at least one marker may be used or any mixture of the four. The method may also include the identification of cytokeratin-19.

1 . A method for the identification of lung cancer comprising: 
 isolating blood or non-lung tissue from a patient, and    identifying the presence of 7018 marker encoded by a polynucleotide comprising at least 17 nucleotides of SEQ ID NO: 17 (p7018, ATCC accession No. PTA-3472, deposited on Jun. 21, 2001).    
     
     
         2 . The method of  claim 1 , further comprising identifying the presence of the marker cytokeratin-19.  
     
     
         3 . The method of  claim 1  wherein said identification is by RT-PCR.  
     
     
         4 . The method of  claim 1  wherein said identification is by antibody binding.  
     
     
         5 . The method of  claim 1  wherein said patient is a mammal.  
     
     
         6 . The method of  claim 5  wherein said mammal is a human, dog, or cat.  
     
     
         7 . A method for the isolation or removal of metastatic cancer cells, comprising: 
 treating cells or a non-lung tissue containing cancer cells with antibodies specific for 7018 marker encoded by a polynucleotide comprising at least 17 nucleotides of SEQ ID NO: 17 (p7018, ATCC accession No. PTA-3472, deposited on Jun. 21, 2001).    
     
     
         8 . The method of  claim 7  further comprising treating said cells with antibodies specific for the marker cytokeratin-19.  
     
     
         9 . The method of  claim 7  wherein said antibodies are bound to a moiety selected from the group consisting of metallic particles, fluorescent particles, chromatography beads, a chromatography gel and a solid support.  
     
     
         10 . A polynucleotide comprising at least 17 nucleotides of SEQ ID NO: 17 (p7018, ATCC accession No. PTA-3472, deposited on Jun. 21, 2001).  
     
     
         11 . A method for the identification of metastases of a solid tumor in a patient, comprising: isolating blood or bone marrow from said patient; and identifying the presence of 7018 marker encoded by a polynucleotide comprising at least 17 nucleotides of SEQ ID NO: 17 (p7018, ATCC accession No. PTA-3472, deposited on Jun. 21, 2001).  
     
     
         12 . The method of  claim 11 , wherein said solid tumor is selected from the group consisting of bile duct, colon, breast, uterus, esophagus, and larynx.  
     
     
         13 . A method for the identification of a carcinoma, comprising: obtaining a cancer cell; and identifying the presence of marker 7018 encoded by a polynucleotide comprising at least 17 nucleotides of SEQ ID NO: 17 (p7018, ATCC accession No. PTA-3472, deposited on Jun. 21, 2001).